fbpx

Clinical Evidence

Published studies and evidence support DoseMeRx achieving therapeutic doses of important medications to streamline operations, improve drug effectiveness and reduce adverse events.

Peer-reviewed Literature

DoseMeRx has demonstrated clear clinical and operational benefits in independent peer-reviewed studies. 

  • DoseMeRx (Bayesian estimation) accurately identifies patients at risk of AKI from just one assay
    Authors: Chavada R, Ghosh N, Sandaradura I, Maley M, Van Hal SJ. | Download Paper
  • Comparing dosage adjustment methods for once-daily tobramycin in paediatric and adolescent patients with cystic fibrosis.
    Authors: Hennig S, Holthouse F, Staatz CE. |Download Paper
  • Evaluation of Tobramycin Exposure Predictions in Three Bayesian Forecasting Programmes Compared with Current Clinical Practice in Children and Adults with Cystic Fibrosis.
    Authors:  Burgard M, Sandaradura I, van Hal SJ, Stacey S, Hennig S.| Download Paper
  • Bayesian algorithms (such as those used in the models within DoseMeRx) enable sophisticated decision support that improves outcomes by customizing therapeutic drug doses for individual patients
    Authors:  M Neely | Download Paper



White Papers

See how easily DoseMe can help you overcome challenges affecting your health system and how our customers are benefiting from DoseMeRx.

Start your free trial

See how easy DoseMeRx is to operate and integrate into your workday.

By signing up you'll be kept in the loop by email on how to evaluate DoseMeRx and all it's nifty features.

HIPAA Privacy Statement | Privacy policy | DoseMe & the GDPR | Copyright © 2012 - 2018 DoseMe Pty Ltd. All Rights Reserved.
DoseMe® is a registered trademark of DoseMe Pty Ltd. DoseMeRx℠ and DoseMe℞℠ are service marks of DoseMe LLC.